Company Overview: Neumus

Industry News

9 Nov

Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee

COSTA MESA, CA–(Marketwired – Nov 9, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) (the “Company”) today announced that it has submitted a demand commencing arbitration against Schneider Finance, LLC and SB Securities, Ltd., both affiliates of Schneider Brothers Ltd., as well as other individuals. SB Securities, Ltd. also uses the name “Schneider...

Read more

6 Nov

NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) and Ocular Diseases (NB2222) at Upcoming Scientific Meetings

COSTA MESA, CA–(Marketwired – Nov 6, 2017) – NEMUS Bioscience, Inc. ( OTCQB :NMUS ) announced that data obtained from the company’s research and development partner, the University of Mississippi (UM), will be presented at upcoming scientific meetings in November. Research under the direction of Dr. Kenneth Sufka (University of Mississippi) utilizing cannabinoid research...

Read more

22 Jun

Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)

COSTA MESA, CA–(Marketwired – Jun 22, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that tetrahydrocannabinol (THC) derived from NB1111, the proprietary Nemus prodrug of THC, achieved significant tissue concentrations in multiple compartments of the eye that correlated with the lowering of IOP in a normotensive...

Read more

9 May

Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Receives Second Patent Issued in the United States Related to Proprietary Delivery Mechanisms for Treatment of Glaucoma

COSTA MESA, CA–(Marketwired – May 9, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that an additional United States patent has been granted covering the company’s proprietary prodrug of THC, THC-valine-hemisuccinate (THCVHS), as well as other amide-ester forms of cannabinoid-based molecules, for use in the treatment...

Read more

22 Mar

NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms

COSTA MESA, CA–(Marketwired – Mar 22, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) and the company’s discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA...

Read more

20 Mar

Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

COSTA MESA, CA–(Marketwired – Mar 20, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address